Jag Capital Management LLC Raises Stake in Natera, Inc. (NASDAQ:NTRA)

Jag Capital Management LLC lifted its position in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 25.6% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,679 shares of the medical research company's stock after buying an additional 26,394 shares during the quarter. Natera makes up 2.4% of Jag Capital Management LLC's investment portfolio, making the stock its 17th largest position. Jag Capital Management LLC owned about 0.10% of Natera worth $18,338,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of NTRA. LRI Investments LLC acquired a new stake in shares of Natera in the fourth quarter worth approximately $29,000. Rakuten Securities Inc. boosted its position in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after acquiring an additional 119 shares during the last quarter. ORG Partners LLC acquired a new stake in shares of Natera in the first quarter worth approximately $32,000. EverSource Wealth Advisors LLC boosted its position in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after acquiring an additional 261 shares during the last quarter. Finally, Principal Securities Inc. boosted its position in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after acquiring an additional 59 shares during the last quarter. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Natera Stock Down 0.1%

NTRA opened at $167.96 on Friday. The firm has a market capitalization of $22.93 billion, a P/E ratio of -114.26 and a beta of 1.74. The firm's 50 day moving average is $158.92 and its 200-day moving average is $158.59. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business's revenue was up 36.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) earnings per share. Equities analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $140.78, for a total value of $563,120.00. Following the completion of the sale, the director now owns 9,704 shares in the company, valued at approximately $1,366,129.12. The trade was a 29.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Steven Leonard Chapman sold 9,563 shares of Natera stock in a transaction on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the completion of the sale, the chief executive officer now owns 212,541 shares of the company's stock, valued at approximately $29,417,799.81. This trade represents a 4.31% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 59,755 shares of company stock worth $8,898,589. Insiders own 7.60% of the company's stock.

Analysts Set New Price Targets

NTRA has been the topic of several research analyst reports. Royal Bank Of Canada initiated coverage on shares of Natera in a research report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 target price on the stock. BTIG Research reissued a "buy" rating on shares of Natera in a research report on Friday, February 28th. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Robert W. Baird lifted their price target on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Piper Sandler lifted their price target on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.